In:
International Journal of Molecular Sciences, MDPI AG, Vol. 23, No. 19 ( 2022-10-01), p. 11629-
Abstract:
Brain-tumor-initiating cells (BTICs) of proneural and mesenchymal origin contribute to the highly malignant phenotype of glioblastoma (GB) and resistance to current therapies. BTICs of different subtypes were challenged with oxidative phosphorylation (OXPHOS) inhibition with metformin to assess the differential effects of metabolic intervention on key resistance features. Whereas mesenchymal BTICs varied according to their invasiveness, they were in general more glycolytic and less responsive to metformin. Proneural BTICs were less invasive, catabolized glucose more via the pentose phosphate pathway, and responded better to metformin. Targeting glycolysis may be a promising approach to inhibit tumor cells of mesenchymal origin, whereas proneural cells are more responsive to OXPHOS inhibition. Future clinical trials exploring metabolic interventions should account for metabolic heterogeneity of brain tumors.
Type of Medium:
Online Resource
ISSN:
1422-0067
DOI:
10.3390/ijms231911629
Language:
English
Publisher:
MDPI AG
Publication Date:
2022
detail.hit.zdb_id:
2019364-6
SSG:
12
Bookmarklink